论文部分内容阅读
目的:观察参雄抗癌丸(SXACP)对H22荷瘤小鼠的抑瘤作用及其机制。方法:将移植H22肝癌瘤株的60只昆明小鼠随机分成5组,分别为模型组、5-FU组、参雄抗癌丸高剂量(SXACP)组、中剂量(SXACP)组、低剂量(SXACP)组,连续用药10天后,比较各组的抑瘤率、VEGF表达。结果:高浓度的(SXACP)在体内对H22肿瘤细胞的生长有明显的抑制作用,对肿瘤组织VEGF的表达有显著的抑制作用。结论:SXACP对肝癌细胞的增殖有明显的抑制作用,其机制与VEGF表达有关。
Objective: To observe the anti-tumor effect of Shenxiong anticancer pill (SXACP) on H22 tumor-bearing mice and its mechanism. Methods: Sixty Kunming mice transplanted with H22 hepatoma cell line were randomly divided into five groups: model group, 5-FU group, SXACP group, SXACP group, low dose (SXACP) group. After 10 consecutive days, the tumor inhibition rate and VEGF expression in each group were compared. Results: High concentration of SXACP significantly inhibited the growth of H22 tumor cells in vivo and significantly inhibited the expression of VEGF in tumor tissues. Conclusion: SXACP can significantly inhibit the proliferation of hepatocellular carcinoma cells. The mechanism is related to the expression of VEGF.